How do Humira and Skyrizi work?
Humira (adalimumab) is a TNF-alpha inhibitor that blocks tumor necrosis factor, a protein driving inflammation in autoimmune diseases.[1] Skyrizi (risankizumab-rzaa) targets IL-23, a different cytokine in the same inflammatory pathway, offering a more selective approach.[2][1]
What conditions do they treat?
Humira treats a broad range: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.[1] Skyrizi focuses on fewer: moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease.[2]
How are they administered and dosed?
Humira uses subcutaneous injections every 1-2 weeks (e.g., 40 mg biweekly after loading).[1] Skyrizi starts with 150 mg subcutaneous injections at weeks 0 and 4, then every 12 weeks for psoriasis or psoriatic arthritis; Crohn's follows a similar induction then 180 mg every 8 weeks.[2] Skyrizi's less frequent dosing cuts injection burden.
How effective are they head-to-head?
Skyrizi often shows higher skin clearance in psoriasis trials (e.g., 75-90% PASI 90 response at week 52 vs. Humira's 40-60%).[3][2] In psoriatic arthritis, Skyrizi matches or exceeds Humira on joint/skin outcomes. Crohn's data positions Skyrizi as comparable or better for endoscopic response.[4][1] Direct comparisons remain limited.
What side effects should patients watch for?
Both carry infection risks (e.g., upper respiratory, TB reactivation) and rare serious issues like lymphoma or heart failure.[1][2] Humira has more injection-site reactions; Skyrizi reports fewer but similar overall safety. Skyrizi avoids TNF-related risks like demyelinating disorders.[3]
Who's the manufacturer and how much do they cost?
AbbVie makes both. Humira lists around $6,000-$7,000 monthly (U.S. cash price); Skyrizi is similar at $5,000-$6,000 but benefits from less frequent dosing.[5] Insurance/copay cards often lower out-of-pocket costs.
Why switch from Humira to Skyrizi?
Patients switch for inadequate response, convenience (fewer shots), or selectivity (Skyrizi for IL-23-driven disease). Biosimilars erode Humira market share since 2023, while Skyrizi grows.[6]
Patent and availability details
Humira's key patents expired 2023, enabling U.S. biosimilars.[7] Skyrizi's main composition patent runs to 2033 (expires October 26, 2033); method patents extend further.[8] Check DrugPatentWatch.com for updates on challenges.[8]
[1]: Humira prescribing information, AbbVie.
[2]: Skyrizi prescribing information, AbbVie.
[3]: Head-to-head trials (e.g., IMMvent, KEEPsAKE), NEJM/JAMA Dermatology.
[4]: Skyrizi Crohn's trials (INDUCE, MOTIVATE), FDA approvals.
[5]: GoodRx pricing data (2024 averages).
[6]: AbbVie earnings reports, Q4 2023.
[7]: FDA biosimilar approvals tracker.
[8]: DrugPatentWatch.com/patent/US10086093 (Skyrizi).